Biomarker discovery offers hope for new TB vaccine development
A team of scientists from the University of Cape Town, Oxford University and the London School of Hygiene & Tropical Medicine have made a discovery that reveals how we can improve development of more effective vaccines against tuberculosis.
Community Engagement
In 2012 SATVI developed a drama production to promote awareness about TB vaccine clinical research, titled “Carina’s Choice” with learners from Worcester Secondary School as actors and UCT drama school students as mentors. A very successful roadshow...
Accredited UCT Research Centre
The South African Tuberculosis Vaccine Initiative (SATVI) is an accreditated Research Centre of the University of Cape Town.
Kick TB Schools Program 17- 27 May 2016
On Tuesday 17 May 2016, SATVI kicked off a districtwide TB awareness raising program, in partnership with TB Alliance, the Western Cape Education Department, AERAS, TB Care (USAID), in Robertson.
Our Research Outputs
The past 15 years we have conducted 22 Phase I–IV trials of BCG and 9 novel TB vaccine candidates, among more than 25,000 research participants. Since 2006 our publication output stands at more than 175 co-authored papers.


Thursday, 30 June 2016

The SATVI Field Site laboratory has received verfication of their proficiency in PBMC isolation and Cryopreservation which was assessed by the Immunology Quality Assessment Contract Laboratory (IQA) at the Duke Human Vaccine Institute (HVC. 

Publication Date:
Thursday, June 30, 2016 - 12:45

Researchers are the South African Tuberculosis Vaccine Initiative (SATVI) have acquired a Tecan Freedom EVO 150, to be used as a robotic liquid handling platform

Publication Date:
Monday, June 20, 2016 - 21:45

We are inviting applications for a postdoctoral fellowship in systems immunology to conduct research on a newly funded project aimed at identifying common immune signatures and mechanisms in humans and animal models of TB. Closing Date  30 July 2016

Publication Date:
Monday, June 13, 2016 - 15:30

The Laboratories of the South African Tuberculosis Vaccine Initiative have been approved to conduct tests in A5343, in support of  Protocol A5343, A Trial of the Safety, Tolerability, and Pharmacokinetics of Bedaquiline and Delamanid.

Publication Date:
Friday, June 10, 2016 - 12:45